Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1932 2
1949 1
1951 1
1952 6
1953 4
1954 10
1955 5
1956 3
1957 4
1958 4
1959 1
1960 2
1961 5
1962 3
1963 4
1964 6
1966 2
1967 6
1968 8
1969 11
1970 19
1971 22
1972 30
1973 22
1974 37
1975 29
1976 23
1977 18
1978 15
1979 11
1980 13
1981 21
1982 18
1983 24
1984 35
1985 25
1986 40
1987 40
1988 48
1989 43
1990 47
1991 37
1992 43
1993 56
1994 53
1995 54
1996 54
1997 50
1998 46
1999 58
2000 59
2001 56
2002 42
2003 47
2004 64
2005 56
2006 57
2007 76
2008 67
2009 69
2010 91
2011 88
2012 92
2013 102
2014 113
2015 104
2016 102
2017 94
2018 98
2019 127
2020 122
2021 139
2022 127
2023 128
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

3,048 results

Results by year

Filters applied: . Clear all
Page 1
Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W, Fan W, Wu F, Shi Z, Wang Z, Yu M, Zhai Y, Chang Y, Pan C, Li G, Kahlert UD, Zhang W. Di W, et al. Cancer Sci. 2022 Feb;113(2):756-769. doi: 10.1111/cas.15236. Epub 2021 Dec 24. Cancer Sci. 2022. PMID: 34881489 Free PMC article.
RESULTS: CD161 was enriched in high-grade gliomas and isocitrate dehydrogenase (IDH)-wildtype glioma. CD161 acted as a potential biomarker for the mesenchymal subtype of glioma and an independent prognostic factor for the overall survival (OS) of patients wit …
RESULTS: CD161 was enriched in high-grade gliomas and isocitrate dehydrogenase (IDH)-wildtype glioma. CD161 acted as a potenti …
Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages.
Ochocka N, Segit P, Walentynowicz KA, Wojnicki K, Cyranowski S, Swatler J, Mieczkowski J, Kaminska B. Ochocka N, et al. Nat Commun. 2021 Feb 19;12(1):1151. doi: 10.1038/s41467-021-21407-w. Nat Commun. 2021. PMID: 33608526 Free PMC article.
We demonstrate an unforeseen molecular heterogeneity among myeloid cells in naive and glioma-bearing brains, validate selected marker proteins and show distinct spatial distribution of identified subsets in experimental gliomas. We find higher expression of MHCII en …
We demonstrate an unforeseen molecular heterogeneity among myeloid cells in naive and glioma-bearing brains, validate selected marker …
The role of microglia and macrophages in glioma maintenance and progression.
Hambardzumyan D, Gutmann DH, Kettenmann H. Hambardzumyan D, et al. Nat Neurosci. 2016 Jan;19(1):20-7. doi: 10.1038/nn.4185. Nat Neurosci. 2016. PMID: 26713745 Free PMC article. Review.
There is a growing recognition that gliomas are complex tumors composed of neoplastic and non-neoplastic cells, which each individually contribute to cancer formation, progression and response to treatment. ...TAMs are recruited to the glioma environment, have immun …
There is a growing recognition that gliomas are complex tumors composed of neoplastic and non-neoplastic cells, which each individual …
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.
Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM. Arrieta VA, et al. J Clin Invest. 2023 Jan 17;133(2):e163447. doi: 10.1172/JCI163447. J Clin Invest. 2023. PMID: 36647828 Free PMC article. Review.
To exploit the maximum therapeutic potential of ICB for patients with glioma, understanding the different aspects of glioma-related tumor immune responses is of critical importance. In this Review, we discuss contributing factors that distinguish subsets of patients …
To exploit the maximum therapeutic potential of ICB for patients with glioma, understanding the different aspects of glioma-re …
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, Patiño-García A, Dobbs J, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, Puigdelloses M, Laspidea V, Astigarraga I, Lopez-Ibor B, Cruz O, Oscoz Lizarbe M, Hervas-Stubbs S, Alkorta-Aranburu G, Tamayo I, Tavira B, Hernandez-Alcoceba R, Jones C, Dharmadhikari G, Ruiz-Moreno C, Stunnenberg H, Hulleman E, van der Lugt J, Idoate MÁ, Diez-Valle R, Esparragosa Vázquez I, Villalba M, de Andrea C, Núñez-Córdoba JM, Ewald B, Robbins J, Fueyo J, Gomez-Manzano C, Lang FF, Tejada S, Alonso MM. Gállego Pérez-Larraya J, et al. N Engl J Med. 2022 Jun 30;386(26):2471-2481. doi: 10.1056/NEJMoa2202028. N Engl J Med. 2022. PMID: 35767439 Clinical Trial.
BACKGROUND: Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been evaluated in patients with pediatric gliomas elsewhere in the brain, but data regarding on …
BACKGROUND: Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor prognosis, with a median survival of less tha …
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W. Platten M, et al. Nature. 2021 Apr;592(7854):463-468. doi: 10.1038/s41586-021-03363-z. Epub 2021 Mar 24. Nature. 2021. PMID: 33762734 Free PMC article. Clinical Trial.
Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma(1-3). The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocom …
Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma(1-3). The most common IDH1 mutatio …
Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance.
Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, de Groot M, Quail DF, Tillard L, Gadiot J, Huse JT, Brandsma D, Westerga J, Watts C, Joyce JA. Akkari L, et al. Sci Transl Med. 2020 Jul 15;12(552):eaaw7843. doi: 10.1126/scitranslmed.aaw7843. Sci Transl Med. 2020. PMID: 32669424
Here, we investigated how radiotherapy changes the relative abundance and phenotypes of brain-resident MG and peripherally recruited monocyte-derived macrophages (MDMs) in glioblastoma. We identified radiation-specific, stage-dependent MG and MDM gene expression signatures …
Here, we investigated how radiotherapy changes the relative abundance and phenotypes of brain-resident MG and peripherally recruited …
Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction.
Wang ZL, Zhang CB, Liu YQ, Wang Z, Jiang T. Wang ZL, et al. CNS Neurosci Ther. 2019 Aug;25(8):876-883. doi: 10.1111/cns.13120. Epub 2019 Mar 26. CNS Neurosci Ther. 2019. PMID: 30912613 Free PMC article.
OBJECTIVE: To investigate the relationship between tumor characteristics and the preoperative counts of immune cells in peripheral blood test in glioma patients. METHODS: We included 260 WHO grades II-IV patients who had preoperative peripheral blood test res …
OBJECTIVE: To investigate the relationship between tumor characteristics and the preoperative counts of immune cells in peripheral bl …
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B, Décarie JC, Théoret Y, Métras MÉ, Sultan S, Cantin É, Routhier MÈ, Caru M, Legault G, Bouffet É, Lafay-Cousin L, Hukin J, Erker C, Jabado N. Perreault S, et al. BMC Cancer. 2019 Dec 27;19(1):1250. doi: 10.1186/s12885-019-6442-2. BMC Cancer. 2019. PMID: 31881853 Free PMC article.
BACKGROUND: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. ...Group 3 includes patients with progressing/refractory glioma with KIAA1549-BRAF fusion. Group 4 includes othe …
BACKGROUND: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conven …
3,048 results